Clinical Trials
34 trialsI-SPY
QuantumLeap Healthcare Collaborative
9-ING-41 in Patients With Advanced Cancers
Actuate Therapeutics Inc.
Dose-finding Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of SNB-101(SN-38) in Patients With Tumors
SN BioScience
Optimizing and Personalising Azacitidine Combination Therapy for Treating Solid Tumours QPOP and CURATE.AI
National University Hospital, Singapore
HS-10502
Jiangsu Hansoh Pharmaceutical Co., Ltd.
Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple Standard Chemotherapy or Immunotherapy Agents in Patients With Advanced Malignancies
M.D. Anderson Cancer Center
Phenomenal
MedSIR
Veliparib and Irinotecan Hydrochloride in Treating Patients With Cancer That Is Metastatic or Cannot Be Removed by Surgery
National Cancer Institute (NCI)
CA225200
US Oncology Research
SMMART Adaptive Clinical Treatment (ACT) Trial
OHSU Knight Cancer Institute
Study to Evaluate the Safety and Tolerability of Andecaliximab as Monotherapy and in Combination With Chemotherapy in Participants With Advanced Solid Tumors
Gilead Sciences
Irinotecan and Capecitabine in Treating Patients With Solid Tumors
Montefiore Medical Center
A Phase II Study of Irinotecan in 3 Line or More Therapy in Local Recurrence or Metastatic Breast Cancer
Liaoning Cancer Hospital & Institute
Study of Pembrolizumab Plus Chemotherapy in Patients With Advanced Cancer (PembroPlus)
Western Regional Medical Center
Irinotecan for Advanced and Metastatic Breast Cancer
Liaoning Cancer Hospital & Institute
Irinotecan and Temozolomide in Treating Patients With Breast Cancer Who Have Received Previous Treatment for Brain Metastases
University of California, San Francisco
Safety Study of the Drug MM-151 in Patients With Advanced Solid Tumors Resisting Ordinary Treatment
Merrimack Pharmaceuticals
Trastuzumab and Irinotecan in Treating Patients With HER2/Neu Positive Metastatic Breast Cancer
University of California, San Francisco
Irinotecan Plus Gemcitabine in Treating Patients With Unresectable or Metastatic Solid Tumors
Northwestern University
Irinotecan and Docetaxel in Treating Patients With Refractory Metastatic Breast Cancer
Alliance for Clinical Trials in Oncology
Irinotecan and Cetuximab in Treating Patients With Metastatic Breast Cancer
Alliance for Clinical Trials in Oncology
A Safety Study of MM-121 With Cetuximab and Irinotecan in Patients With Advanced Cancers
Merrimack Pharmaceuticals
Irinotecan in Treating Patients With Refractory Metastatic Breast Cancer
Alliance for Clinical Trials in Oncology
A Study Evaluating INIPARIB in Combination With Chemotherapy to Treat Triple Negative Breast Cancer Brain Metastasis
Sanofi
Irinotecan and Etoposide in Treating Patients With Recurrent, Locally Advanced, or Metastatic Breast Cancer
University of Arizona
A Pilot Study of Irinotecan in Patients With Breast Cancer and CNS Metastases
University of California, Irvine
7-Hydroxystaurosporine and Irinotecan Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors or Triple Negative Breast Cancer (Currently Accruing Only Triple-negative Breast Cancer Patients Since 6/8/2007)
National Cancer Institute (NCI)
A Phase II Safety and Tolerability Study of Bevacizumab When Added to Single-agent Chemotherapy to Treat Patient With Breast Cancer Metastatic to Brain
Duke University
PROCEED
National Cancer Center, Korea
Irinotecan in Treating Patients With Metastatic or Recurrent Breast Cancer
Northwestern University
Phase II Study of Irinotecan/Capecitabine in Patients With Antracycline/Taxane Pretreated MBC
National Cancer Center, Korea
Irinotecan and Capecitabine in Treating Women With Advanced Breast Cancer
Roswell Park Cancer Institute
Irinotecan in Patients With Advanced Metastatic Breast Cancer Who Have Experienced Failure of an Anthracycline, a Taxane, and Capecitabine
Pfizer
Phase I Study of PN401, Fluorouracil, Leucovorin and CPT-11 in Patients With Solid Tumors
Wellstat Therapeutics